Zacks: Analysts Expect West Pharmaceutical Services Inc. (WST) Will Post Quarterly Sales of $462.78 Million

Wall Street analysts predict that West Pharmaceutical Services Inc. (NYSE:WST) will post $462.78 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for West Pharmaceutical Services’ earnings. The highest sales estimate is $466.00 million and the lowest is $457.05 million. West Pharmaceutical Services posted sales of $447.50 million in the same quarter last year, which would indicate a positive year over year growth rate of 3.4%. The firm is scheduled to announce its next earnings report on Thursday, July 25th.

According to Zacks, analysts expect that West Pharmaceutical Services will report full year sales of $1.81 billion for the current year, with estimates ranging from $1.80 billion to $1.82 billion. For the next year, analysts forecast that the company will post sales of $1.95 billion, with estimates ranging from $1.93 billion to $1.97 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, April 25th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.08. West Pharmaceutical Services had a return on equity of 16.38% and a net margin of 12.53%. The company had revenue of $443.50 million during the quarter, compared to analysts’ expectations of $431.00 million. During the same quarter in the prior year, the business posted $0.62 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year.

WST has been the subject of several research reports. Zacks Investment Research cut West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research note on Saturday, April 27th. Jefferies Financial Group cut West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $122.00 target price for the company. in a research note on Wednesday, May 1st. Finally, William Blair initiated coverage on West Pharmaceutical Services in a research note on Tuesday, April 23rd. They set an “outperform” rating and a $112.16 target price for the company.

In related news, VP Daniel Malone sold 4,458 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $123.03, for a total transaction of $548,467.74. Following the completion of the transaction, the vice president now owns 33,478 shares of the company’s stock, valued at $4,118,798.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.70% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in WST. Financial Gravity Wealth Inc. purchased a new stake in shares of West Pharmaceutical Services during the first quarter valued at $25,000. Berman Capital Advisors LLC purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter valued at $27,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of West Pharmaceutical Services by 188.1% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 242 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 158 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in shares of West Pharmaceutical Services by 9,703.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 2,836,204 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 2,807,272 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in shares of West Pharmaceutical Services by 208.7% during the first quarter. Quadrant Capital Group LLC now owns 318 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 215 shares during the last quarter. 92.56% of the stock is owned by institutional investors and hedge funds.

WST stock traded up $0.23 during trading hours on Tuesday, hitting $116.29. 154,737 shares of the stock traded hands, compared to its average volume of 416,035. West Pharmaceutical Services has a one year low of $90.63 and a one year high of $125.09. The stock has a market capitalization of $8.55 billion, a P/E ratio of 41.38, a P/E/G ratio of 3.61 and a beta of 1.29. The company has a quick ratio of 2.13, a current ratio of 2.88 and a debt-to-equity ratio of 0.19.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Investors of record on Wednesday, July 24th will be paid a dividend of $0.15 per share. The ex-dividend date is Tuesday, July 23rd. This represents a $0.60 annualized dividend and a yield of 0.52%. West Pharmaceutical Services’s dividend payout ratio is currently 21.35%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Article: Why is a lock-up period needed for an IPO?

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.